Month: September 2021

In recent pre- clinical studies, Polyrizon products showed strong potential in preventing human coronavirus 229E and Influenza Virus H1N1 from interacting with epithelial host cells and by inhibiting cells’ death. OMER, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) —  Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, will evaluate the viral infection prophylaxis effect of its innovative product candidate against the Delta variant of the coronavirus(lineage B.1.617.2), in-vitro. This study follows recent pre-clinical studies showed strong potential against human coronavirus 229E and influenza virus infection. The...

Figure 1:Location of Metallic Metals’ Starr gold-silver project with respect to adjacent properties including the Moss Lake gold deposit (sources: 2013 NI 43-101 Technical Report and PEA for the Moss Lake Project and Kesselrun Resources October 7, 2020 news release)Figure 2:Planned drilling (red) in the Central portion of the Starr Property with known showings and gold values from grab and soil sampling, underlain by TMI (Total Magnetic Intensity from the First Vertical Derivative)Figure 3:Planned drilling (red) on the Eastern Side of the Starr Property with known showings and gold values from grab and soil sampling, underlain by TMI (Total Magnetic Intensity from the First Vertical Derivative)Figure 4:Planned drilling (red) on the West Side of the Starr Property with known...

Figure 1.Effects of TSC on transcutaneous oxygen pressure (tcpO2). The graph was created by subtracting the median placebo response from the dose and time matched median TSC response.CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders. The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022. The full text of the letter follows:  Diffusion Pharmaceuticals Shareholder Letter September 9, 2021 Dear Fellow Stockholders, I assumed the...

SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation of new preclinical data on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) being developed for the treatment of metastatic breast cancer and other women’s cancers, at the 1st JCA-AACR Precision Cancer Medicine International Conference being held virtually from September 10-12, 2021 (U.S.) and September 11-12 (Japan). A virtual e-poster presentation titled, “Complete Estrogen Receptor (ER) Antagonism As An Optimal Approach for ER-Positive Breast Cancer Drug Development,”...

MONTREAL, Sept. 09, 2021 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland” or the “Corporation”) (TSX-V: MD) is pleased to announce that the Board of Directors has approved the nomination of Mr. Jean des Rivières as a Director of the Corporation. “It is a privilege to have Mr. des Rivières join our team. His diversified experience in the exploration and mining industries spanning over 35 years while working in more than 50 countries, makes him an ideal candidate for our Board. He most recently held the position of Vice President Metals Exploration at BHP and previously held managerial and technical positions at Rio Algom, BHP and Noranda. After a successful career, he recently joined the board of directors of First Majestic Silver Corp. and Montero Mining and Exploration Ltd. Mr. des Rivières holds a Bachelor of Science degree...

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives, announced today that it is scheduled to host a key opinion leader (KOL) webinar on IgA Nephropathy (IgAN or Berger’s Disease) at 12:00 p.m. ET on Monday, September 20, 2021. The event will feature presentations by KOLs Richard Lafayette M.D., Stanford University Medical Center, and Jonathan Barratt, Ph.D., FRCP, University of Leicester. Dr. Lafayette will discuss the rationale for targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) in IgAN. Dr. Barratt will discuss data from trials targeting BLyS and APRIL in IgAN patients, including the Phase 2a JANUS study of atacicept,...

VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) — ParcelPal Logistics Inc. (the “Company” or “ParcelPal”), (OTC:PTNYF) (CSE:PKG) (FSE:PT0) is pleased to announce that as part of the Company’s broader plan to continue to diversify its customer base and execute on additional profitable business engagements, it has expanded its services with an existing large meal kit delivery company, for which we already provide same-day delivery courier services in Vancouver and Calgary. Under the expanded service offering, ParcelPal will be using electric refrigerated cargo vans to deliver meal kits from our client’s facility to their end customers. As this scales, we intend to expand this service to include white glove same-day grocery delivery, placing an even greater emphasis on the customer experience. CEO Rich Wheeless...

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Fox River Resources Corporation (the “Company” or “Fox River”) (CSE: FOX) is pleased to announce that it has engaged Hatch Ltd., together with JESA Technologies LLC and DMT Consulting Limited, for the preparation of a National Instrument (“NI”) 43-101 preliminary economic assessment (“PEA”) study on the Company’s 100% owned Martison Phosphate Project (“Martison”), located near Hearst, Ontario. The objectives of the PEA include:Completion of an independent PEA-level engineering analysis of the project with the aim of producing phosphate fertilizer products from a fully integrated facility; Providing an estimate of the potential economic value of the project; Providing an estimate of the project’s capital costs, operating costs, as well as sustaining capital costs; Providing a conceptual...

CELEBRATION, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) — KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The prerecorded presentation will be available starting at 9:00 a.m., ET on September 13, 2021, and can be accessed via the conference’s virtual platform by registered conference attendees. Details of the presentation are as follows:Event: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: September 13-15, 2021Time: Presentations available starting at 9:00 a.m., ET on September 13, 2021Registration: https://hcwevents.com/annualconference/About...

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), today announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies and Fc-fusion proteins. Named NGL-Impact® A Hi pH, the new ligand is the first to address antibody aggregation in low pH elution buffers. While developed specifically to address pH sensitive antibodies and Fc-fusion proteins, NGL-Impact A Hi pH ligand demonstrates high performance for all antibodies, and can be considered for “platform” use due to its broad pH operating range. Ralf Kuriyel, Repligen Senior Vice President R&D, said, “This new best-in-class ligand...